Skip to content

Study · Randomized controlled trial · n = 12 · 2004

11 results

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.

Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O

Diabetes1 Sept 2004Cited by 189 (Europe PMC)

PMID15331551 (opens in a new tab)DOI10.2337/diabetes.53.9.2397 (opens in a new tab)PepBankPUB-15331551
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy volunteers, glucose profiles were superimposable during exenatide and placebo infusions.

    In plain wordsIn healthy volunteers, glucose profiles were similar with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucose profiles
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucose profiles were superimposable between the exenatide and placebo arms.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  2. 02HumanRandomized controlled trialMechanism

    In healthy volunteers with euglycemic hyperinsulinemia, insulin secretion was approximately 3.5-fold higher with exenatide than placebo.

    In plain wordsIn healthy volunteers at normal glucose levels, exenatide increased insulin secretion versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin secretion during euglycemia
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Measurements

    Insulin secretory rate
    353 pmol/min
    exenatide arm, euglycemic hyperinsulinemia (least-square mean, SE 29)
    Insulin secretory rate
    100 pmol/min
    placebo arm, euglycemic hyperinsulinemia (least-square mean, SE 29)
    Fold difference in insulin secretory rate, exenatide vs placebo
    ≈ 3.5 fold
    euglycemic hyperinsulinemia

    Source sentences

    Summary
    In the presence of euglycemic hyperinsulinemia, ISRs in the exenatide arm were approximately 3.5-fold higher than in the placebo arm (353 +/- 29 vs. 100 +/- 29 pmol/min [least-square means +/- SE]).
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  3. 03HumanRandomized controlled trialMechanism

    In healthy volunteers, insulin secretory rates declined similarly at all hypoglycemic steps with exenatide and placebo.

    In plain wordsIn healthy volunteers with low glucose, insulin secretion declined similarly with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInsulin secretion during hypoglycemia
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    However, ISRs declined similarly and rapidly at all hypoglycemic steps (</=4 mmol/l) in both groups.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  4. 04HumanRandomized controlled trialMechanism

    In healthy volunteers, exenatide suppressed glucagon during euglycemia versus placebo.

    In plain wordsIn healthy volunteers at normal glucose levels, exenatide suppressed glucagon versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlucagon during euglycemia
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon was suppressed in the exenatide arm during euglycemia and higher than placebo during hypoglycemia.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  5. 05HumanRandomized controlled trialMechanism

    In healthy volunteers, glucagon was higher with exenatide than placebo during hypoglycemia.

    In plain wordsIn healthy volunteers with low glucose, glucagon was higher with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGlucagon during hypoglycemia
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon was suppressed in the exenatide arm during euglycemia and higher than placebo during hypoglycemia.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  6. 06HumanRandomized controlled trialMechanism

    In healthy volunteers, plasma glucose recovery time was equivalent with exenatide and placebo.

    In plain wordsIn healthy volunteers, glucose recovery time was similar with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucose recovery time
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Plasma glucose recovery time was equivalent for both treatments.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  7. 07HumanRandomized controlled trialMechanism

    In healthy volunteers, cortisol concentration-time area was similar with exenatide and placebo.

    In plain wordsIn healthy volunteers, cortisol exposure was similar with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCortisol concentration-time area
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    The areas under the concentration-time curve from 270 to 360 min for cortisol, epinephrine, norepinephrine, and growth hormone were similar between treatment arms.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  8. 08HumanRandomized controlled trialMechanism

    In healthy volunteers, epinephrine concentration-time area was similar with exenatide and placebo.

    In plain wordsIn healthy volunteers, epinephrine exposure was similar with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeEpinephrine concentration-time area
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    The areas under the concentration-time curve from 270 to 360 min for cortisol, epinephrine, norepinephrine, and growth hormone were similar between treatment arms.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  9. 09HumanRandomized controlled trialMechanism

    In healthy volunteers, norepinephrine concentration-time area was similar with exenatide and placebo.

    In plain wordsIn healthy volunteers, norepinephrine exposure was similar with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeNorepinephrine concentration-time area
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    The areas under the concentration-time curve from 270 to 360 min for cortisol, epinephrine, norepinephrine, and growth hormone were similar between treatment arms.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  10. 10HumanRandomized controlled trialMechanism

    In healthy volunteers, growth hormone concentration-time area was similar with exenatide and placebo.

    In plain wordsIn healthy volunteers, growth hormone exposure was similar with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGrowth hormone concentration-time area
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    The areas under the concentration-time curve from 270 to 360 min for cortisol, epinephrine, norepinephrine, and growth hormone were similar between treatment arms.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).
  11. 11HumanRandomized controlled trialSafety outcome

    In healthy volunteers, adverse events did not differ between exenatide and placebo.

    In plain wordsIn healthy volunteers, adverse events did not differ between exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAdverse events
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.066 pmol/kg/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    There were no differences in adverse events.
    1 context sentence
    Summary · context
    Twelve healthy fasted volunteers were randomized in a triple-blind crossover study to receive either intravenous exenatide (0.066 pmol. kg(-1). min(-1)) or placebo during a 270-min stepwise hyperinsulinemic-hypoglycemic clamp (insulin infusion 0.8 mU. kg(-1). min(-1)).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03819790

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

LMC Diabetes & Endocrinology Ltd.n = 1192 Oct 2018 to 19 Nov 2019

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 25 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.